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Abstract 
Background 
Heart failure (HF) is a complex syndrome associated with a maladaptive innate immune system response that leads to 
deleterious cardiac remodeling. However, the underlying mechanisms of this syndrome are poorly understood. 
Nucleotide-binding oligomerization domain-containing protein 1 (NOD1) is a newly recognized innate immune 
sensor involved in cardiovascular diseases. 
Objectives 
This study evaluated the role of NOD1 in HF progression. 
Methods 
NOD1 was examined in human failing myocardium and in a post-myocardial infarction (PMI) HF model evaluated in 
wild-type (wt-PMI) and Nod1–/– mice (Nod1–/–-PMI). 
Results 
The NOD1 pathway was up-regulated in human and murine failing myocardia. Compared with wt-PMI, hearts from 
Nod1–/–-PMI mice had better cardiac function and attenuated structural remodeling. Ameliorated cardiac function in 
Nod1–/–-PMI mice was associated with prevention of Ca2+ dynamic impairment linked to HF, including smaller and 
longer intracellular Ca2+ concentration transients and a lesser sarcoplasmic reticulum Ca2+ load due to a down-
regulation of the sarcoplasmic reticulum Ca2+-adenosine triphosphatase pump and by augmented levels of the 
Na+/Ca2+ exchanger. Increased diastolic Ca2+ release in wt-PMI cardiomyocytes was related to hyperphosphorylation 
of ryanodine receptors, which was blunted in Nod1–/–-PMI cardiomyocytes. Pharmacological blockade of NOD1 also 
prevented Ca2+ mishandling in wt-PMI mice. Nod1–/–-PMI mice showed significantly fewer ventricular arrhythmias 
and lower mortality after isoproterenol administration. These effects were associated with lower aberrant systolic 
Ca2+ release and with a prevention of the hyperphosphorylation of ryanodine receptors under isoproterenol 
administration in Nod1–/–-PMI mice. 
Conclusions 
NOD1 modulated intracellular Ca2+ mishandling in HF, emerging as a new target for HF therapy. 
Key Words 
Calcium; Cardiac arrhythmia; Cardiac dysfunction; Innate immune system; Myocardial infarction; Ryanodine 
receptor 
Abbreviations and Acronyms 
[Ca2+]i, intracellular Ca
2+ concentration; CaMKII, calcium/calmodulin-dependent protein kinase II; CMR, cardiac 
magnetic resonance; EC, excitation-contraction; EF, ejection fraction; HF, heart failure; ICaL, triggered Ca
2+ current 
through L-type calcium channel; iE-DAP, lauroyl γ-D-glutamyl-meso-diaminopimelic acid; MI, myocardial 
infarction; NCX, Na+/Ca2+ exchanger; NLR, nucleotide-binding oligomerization domain-like receptor; NOD1, 
nucleotide-binding oligomerization domain-containing protein 1; PKA, protein kinase A; PMI, post-myocardial 
infarction; RIP2, receptor-interacting protein 2; RyR, ryanodine receptor; SCR, spontaneous Ca2+ release; SERCA, 
sarcoplasmic reticulum Ca2+-adenosine triphosphatase 2a pump; SR, sarcoplasmic reticulum; VT, ventricular 
tachycardia; wt, wild type 
Heart failure (HF) occurs when the heart is unable to maintain cardiac output at normal filling 
pressures. HF is among the leading causes of death and hospitalization in Western countries and 
constitutes a significant economic burden (1). Despite advances in treatment, the prognosis for HF 
patients remains poor, underscoring the need for new therapeutic options. 
 
HF is characterized by increased cardiac activation of the innate immune system, independent of 
disease etiology (2,3). Although the innate immune system appears to influence clinical outcomes in HF 
patients, use of anti-inflammatory drugs has not yielded the expected benefits in clinical trials (4). Given 
its complexity, the design of new anti-inflammatory HF treatments requires a detailed understanding of 
how the innate immune system influences the development and progression of the disease. 
 
As the first line of host defense against pathogens or environmental damage, the innate immune 
system triggers a proinflammatory response when challenged. Although essential for homeostatic 
responses and tissue repair, chronic activation of the cardiac innate immune system results in deleterious 
cardiac remodeling. The innate immune system is mainly regulated by 2 families of receptors: toll-like 
receptors and nucleotide-binding oligomerization domain-like receptors (NLR). Toll-like receptors are the 
best characterized innate immune receptors in the cardiovascular system (3,4); much less information is 
available on NLR, although they are a current area of active research (5). Nucleotide-binding 
oligomerization domain-containing protein 1 (NOD1), a member of the NLR family, has recently been 
implicated in several cardiovascular pathologies, including atherosclerosis and diabetic cardiomyopathy 
(6,7). NOD1 is expressed in murine heart and, on activation, undergoes a conformational change that 
promotes the activation of receptor-interacting protein 2 (RIP2), ultimately triggering the 
proinflammatory response. Recent findings showed that selective activation of NOD1 induces cardiac 
dysfunction by impairing excitation-contraction (EC) coupling (8). In the heart, EC coupling depends 
primarily on a mechanism called Ca
2+
-induced Ca
2+
 release, which is initiated by an action potential in the 
cardiomyocytes that fires a small influx of Ca
2+
 via sarcolemma L-type Ca
2+
 channels. This triggers a 
large release of Ca
2+
 from the sarcoplasmic reticulum (SR) through ryanodine receptors (RyR), resulting 
in an increased intracellular Ca
2+
 concentration ([Ca
2+
]i) that activates myofilaments, prompting cell 
contraction. Relaxation is achieved by pumping Ca
2+
 to the SR via sarcoplasmic reticulum Ca
2+
-
adenosine triphosphatase 2a (SERCA), whose activity is regulated by phospholamban and across the 
plasma membrane through the Na
+
/Ca
2+
 exchanger (NCX). Impairment of EC coupling is well 
documented in experimental and human HF. Importantly, Ca
2+
 mishandling linked to HF is closely 
related to depressed cardiac function and cardiac arrhythmia development (9). 
 
Because NOD1 activation in wild-type (wt) myocytes impairs EC coupling in a manner similar to that 
described in HF (8), we analyzed whether NOD1 participates in HF progression. 
  
METHODS 
All human and animal studies were performed with the permission of A Coruña and La Paz Hospitals 
on human ethics and animal policy and welfare following recommendations of the Spanish and European 
guidelines (Ref. 2010/63/EU). 
 
As previously described (8), male Nod1
–/–
 mice on a C57BL/6J (6B; 129P2- NOD1
tm1Nnz
/J) 
background were used (provided by G.N.), and C57BL/6J (Jackson Laboratory, Bar Harbor, Maine) wt 
mice were used as control specimens. Expanded methods are presented in the Online Appendix. 
RESULTS 
Immunohistochemical analysis of myocardial tissue obtained from HF patients and unused healthy 
myocardia from transplant donors (healthy hearts) demonstrated higher levels of NOD1 in HF than in 
healthy heart samples, which were localized to the rod-shaped cardiomyocyte population (Figure 1A; 
immunostaining control specimens are presented in Online Figure 1). Immunoblots show higher protein 
levels of NOD1, its specific adaptor RIP2, and the proinflammatory mediator tumor necrosis factor-α in 
HF versus healthy heart tissue (Figures 1B and 1C). We evaluated the relationship among cardiac output, 
ejection fraction (EF), and NOD1 levels. A significant negative correlation was found between NOD1 
and cardiac output or EF in HF patients (Figures 1D and 1E). 
  
 
 
 
Figure 1. NOD1 Overexpressed in Failing Myocardium 
(A) Representative hematoxylin and eosin–stained sections of healthy 
myocardium (HH) (a) and heart failure (HF) myocardium (b) (original 
magnification: 10×). (c to f) Immunohistochemistry staining of 
transversal sections demonstrated that nucleotide-binding 
oligomerization domain-containing protein 1 (NOD1) is higher in 
cardiomyocytes of HF versus HH (original magnification: 10× [c, d]; 
20× [e, f]). Bars = 100 μm. (B, C) Representative Western blots of 
NOD1, receptor-interacting protein 2 (RIP2), tumor necrosis factor-α 
(TNF-α), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
from HH (n = 7; blue bars) and HF (n = 12; orange bars) samples, 
and quantification of Western blots (mean ± SEM). *p < 0.05 versus 
HH. (D, E) Negative correlation between NOD1 protein and cardiac 
output or ejection fraction (EF) in HF patients. Analysis was 
performed using the Pearson correlation. A linear regression of the 
data is shown. 
We next examined NOD1 protein levels in cardiac tissue from mice with HF induced by myocardial 
infarction (MI). NOD1, RIP2, and tumor necrosis factor-α levels were higher in whole hearts of HF-
induced wild-type mice at 6 weeks post-myocardial infarction (wt-PMI) than in equivalent sham-operated 
wt mice (Figures 2A and 2B). Six weeks after MI, mice were analyzed for cardiac function and 
morphometries. Survival was not different between the wt-PMI and Nod1
–/–
-PMI mice (not shown). 
Echocardiography recordings showed that EF (Figure 2C) and fractional shortening (Figure 2D) were 
significantly lower in wt-PMI mice (p < 0.001), whereas Nod1
–/–
-PMI mice exhibited improved EF and 
fractional shortening parameters (Figures 2C and 2D). Cardiac magnetic resonance (CMR) analysis 
supported the prevention of MI-induced cardiac dysfunction in Nod1
–/–
-PMI mice (Figure 2E, Table 1). 
Furthermore, CMR after gadolinium enhancement showed that hearts of Nod1
–/–
-PMI mice had 
significantly smaller infarcts than did wt-PMI mice (Figure 2F). Additionally, wt-PMI mice treated for 
6 weeks with the NOD1 inhibitor nodinitib-1 (10) also exhibited significantly better EF and fractional 
shortening values after PMI (Online Figure 2). 
 
 
 
Figure 2. Effects of NOD1 Absence: Murine HF Model 
(A, B) Representative Western blots of NOD1, RIP2, TNF-α, and 
GAPDH from cardiac tissue of wild-type (wt; blue bars) (n = 5) and 
wild-type post-myocardial infarction (wt-PMI; orange bars) (n = 6) 
mice, and quantification of Western blots (mean ± SEM). (C, D) 
Mean values of the EF and fractional shortening (FS) in wt (n = 3) and 
Nod1–/– (n = 3) mice before and 6 weeks PMI. (E) Representative 2-
chamber short-axis cardiac magnetic resonance images at the end of 
diastole. (F) An example of late-enhanced recordings 20 to 40 min 
following application of gadolinium (Gd)-based contrast agent 
obtained in wt-PMI mice with mean values of quantification in wt (n = 
5) and Nod1–/– (n = 7) mice 6 weeks PMI. Mean ± SEM; Bars = 3 mm. 
*p < 0.05, **p < 0.01, ***p < 0.001 versus wt; #p < 0.05, ###p < 0.001 
versus wt-PMI. LV = left ventricle; other abbreviations as in Figure 1. 
  
Table 1. Macroscopic and Cellular Parameters 
 
Sham-Operated 
 
PMI 
wt Nod1–/– 
 
wt Nod1–/– 
      
Heart rate, beats/min 392.34 ± 5.34 (4) 415.99 ± 20.04 (4)  394.10 ± 15.70 (6) 428.91 ± 26.99 (8) 
SV, μl 38.80 ± 1.10 (4) 31.90 ± 1.03 (4)  27.61 ± 2.73∗ (6) 35.01 ± 1.50† (8) 
CO, ml/min 15.24 ± 0.43 (4) 13.87 ± 0.59 (4)  10.18 ± 1.00∗ (6) 14.98 ± 0.64‡ (8) 
LVWTD, mm 0.57 ± 0.01 (4) 0.52 ± 0.00 (4)  0.80 ± 0.06§ (6) 0.62 ± 0.03† (8) 
IVSWTD, mm 0.43 ± 0.07 (4) 0.42 ± 0.02 (4)  0.55 ± 0.03§ (6) 0.45 ± 0.03 (8) 
HW, mg 211.13 ± 6.60 (12) 200.90 ± 10.80 (9)  257.1 ± 7.80§ (17) 217.00 ± 11.30† (17) 
Body weight, g 26.83 ± 0.70 (12) 26.70 ± 1.90 (9)  29.20 ± 0.80 (17) 30.00 ± 11.30 (17) 
TL, mm 21.80 ± 0.21 (12) 21.33 ± 0.30 (9)  21.50 ± 0.42 (17) 21.9 ± 0.20 (17) 
HW/TL, mg/mm 9.90 ± 0.30 (12) 9.38 ± 0.46 (9)  12.07 ± 0.36‖ (17) 9.63 ± 0.45‡ (17) 
Cell area, μm2 1,963.50 ± 158.00 (17) 2,033.00 ± 141.70 (17)  4,062.00 ± 193.00‖ (35) 3,215.34 ± 126.00‡¶ (32) 
      
 
Values are mean ± SEM (n). 
CO = cardiac output; HW = heart weight; IVSWTD = interventricular septum thickness at end of diastole; LVWTD = left 
ventricular free wall thickness at end diastole; Nod1–/– = nucleotide-binding oligomerization domain-containing protein 1; PMI = 
post-myocardial infarction; SV = stroke volume; TL = tibia length; wt = wild type. ∗ p < 0.01 versus wt. † p < 0.05 versus wt-PMI. 
‡ p < 0.001 versus wt-PMI. § p < 0.05 versus wt. ‖ p < 0.001 versus wt. ¶ p < 0.001 versus Nod1–/–. 
We next analyzed whether the absence of NOD1 attenuates cardiac hypertrophy development in the 
HF model. Heart weights and heart weight–tibia length ratio were significantly higher in wt-PMI mice 
than in noninfarcted wt-mice, although no differences were found in body weights or tibia length among 
the different groups (Table 1). On CMR analysis, end-diastole left ventricular and interventricular septum 
thickness were significantly greater in wt-PMI than wt hearts. By contrast, heart weights and heart 
weight–tibia length ratio in Nod1–/–-PMI mice were significantly lower than in wt-PMI mice and were 
very similar to that of noninfarcted Nod1
–/–
mice (Table 1). Moreover, hearts from Nod1
–/–
-PMI mice did 
not present an increase in end-diastole left ventricular and interventricular septum thickness (Table 1). 
Notably, cardiomyocytes isolated from wt-PMI mice had a significantly larger surface area than did wt 
cardiomyocytes, whereas the surface area of Nod1
–/–
-PMI cardiomyocytes was only moderately increased 
relative to noninfarcted Nod1
–/–
 cardiomyocytes (Table 1). 
 
Next, intracellular Ca
2+
 handling was determined in all groups. Nod1
–/–
-PMI myocytes showed a 
significant amelioration of Ca
2+
 mishandling induced by MI, largely by preventing the decrease in 
amplitude of [Ca
2+
]i transients (Figures 3A and 3B), by increasing the decay time constant of [Ca
2+
]i 
transients (Figure 3C), and by reducing the cell contraction detected in wt-PMI myocytes (Figure 3D). 
We also examined changes in SR Ca
2+
 load by analyzing caffeine-evoked [Ca
2+
]i transients, which were 
weaker in the wt-PMI group than in the wt group (Figure 3E), whereas faster rates of decay were 
observed in wt-PMI cardiomyocytes: 2.95 ± 0.35 s in wt (n = 13 cells/4 mice) and 2.00 ± 0.20 s in wt-
PMI (n = 9 cells/4 mice) (p < 0.05). By contrast, caffeine-evoked [Ca
2+
]i transients (Figure 3E) and their 
decay time in cells from Nod1
–/–
-PMI mice were very similar to those obtained in Nod1
–/–
 cells: 2.60 ± 
0.27 s in the Nod1
–/–
 group (n = 7 cells/3 mice) and 2.46 ± 0.25 s in the Nod1
–/–
-PMI group (n = 10 cells/4 
mice). 
  
 
 
 
Figure 3. NOD1 Deletion and HF Intracellular Ca2+ Mishandling 
(A) Representative line-scan confocal images in cells from wt, wt-PMI, 
Nod1–/–, and Nod1–/–-PMI mice. Mean values of (B) peak fluorescence 
[Ca2+]i transients (F/F0), (C) decay time constant (Tau) and (D) cell 
contraction (CC) in wt (n = 16 cells/5 mice), wt-PMI (n = 33 cells/5 
mice), Nod1–/– (n = 14 cells/3 mice), and Nod1–/–-PMI (n = 24 cells/5 
mice). (E) Mean values of caffeine-evoked [Ca2+]i transients amplitude 
(sarcoplasmic reticulum [SR]-Ca2+ load, F/F0) in wt (n = 16 cells/3 
mice), wt-PMI (n = 21 cells/4 mice), Nod1–/– (n = 12 cells/3 mice), and 
Nod1–/–-PMI (n = 19 cells/4 mice). Mean ± SEM. (F) Representative 
immunoblots of SR Ca2+-adenosine triphosphatase 
2a (SERCA)/GAPDH from hearts of wt (n = 8), wt-PMI (n = 6), Nod1–/– 
(n = 8), and Nod1–/–-PMI (n = 6) mice. (G) Quantification of Western 
blots (mean ± SEM) expressed as percentage versus wt. *p < 0.05, **p < 
0.01, ***p < 0.001 versus wt; #p < 0.05, ##p < 0.01, ###p < 0.001 versus 
wt-PMI. Abbreviations as in Figures 1 and 2. 
Additionally, we analyzed the levels of SERCA in all groups. The SERCA in wt-PMI hearts was 
significantly lower than in wt hearts (p < 0.001), whereas in cardiac tissue from Nod1
–/–
-PMI mice 
SERCA levels remained unchanged (Figures 3F and 3G). 
 
NCX protein levels were significantly higher in wt-PMI heart tissue than in equivalent wt samples, 
whereas similar NCX protein levels were detected in Nod1
–/–
-PMI and Nod1
–/–
 hearts (Online Figure 3). 
Supporting these data, pharmacological blockade of NOD1 with nodinitib-1 in wt-PMI mice prevented 
impairment of systolic Ca
2+
 release and cell contraction and maintained the SR Ca
2+
 load (Online 
Figure 4). 
 
Diastolic Ca
2+
 release was analyzed by determining Ca
2+
 spark frequency and properties. A similar 
number of Ca
2+
 sparks was found in cardiomyocytes from all groups (Figure 4A). Ca
2+
 sparks in wt-PMI 
cardiomyocytes had a larger amplitude and full width at half maximum values than equivalent wt cells, 
and no change was detected in their full duration at half maximum values. Ca
2+
 spark characteristics were 
similar in Nod1
–/–
-PMI and Nod1
–/–
 cardiomyocytes (Online Table 1). Ca
2+
 spark frequencies normalized 
to the SR Ca
2+
 load obtained in each cell showed similar normalized Ca
2+
 spark frequencies in all groups 
(Figure 4B). Confirming these data, no differences were found between groups in overall spark-mediated 
Ca
2+
 leak (Online Figure 5).  
 
 
 
Figure 4. NOD1 Deletion and MI-Induced Diastolic Ca2+ Release 
Summarized data of mean values of (A) Ca2+ sparks frequency and 
(B) normalization of Ca2+ sparks frequency by SR Ca2+ load in wt (n = 
20 cells/4 mice), wt-PMI (n = 49 cells/8 mice), Nod1–/– (n = 24 cells/4 
mice), and Nod1–/–-PMI (n = 37 cells/8 mice). (C) Examples of line-
scan images of spontaneous diastolic Ca2+ release (SCR) recordings 
(Ca2+ wave [top]; spontaneous [Ca2+]i transients release [bottom]) 
from wt-PMI myocytes. (D) Average data of SCR occurrence from wt 
(n = 20 cells/4 mice), wt-PMI (n = 49 cells/8 mice), Nod1–/– (n = 24 
cells/4 mice), and Nod1–/–-PMI (n = 37 cells/8 mice). ***p < 0.001 
versus wt; ###p < 0.001 versus wt-PMI. (E) Representative Western 
blots of ryanodine receptor (RyR) and phosphorylation ryanodine 
receptor (P-RyR) at Ser2808/2814 and RyR in wt, wt-PMI, Nod1–/–, and 
Nod1–/–-PMI mice. (F) Histograms represent the SCR occurrence in 
cardiomyocytes treated for 1 to 2 h with vehicle (Veh), lauroyl γ-D-
glutamyl-meso-diaminopimelic acid (iE-DAP) (40 μg/ml), iE-DAP 
(40 μg/ml) + KT-5720 (KT) (2 μmol/l) or iE-DAP (40 μg/ml) + KN-
93 (KN) (1 μmol/l). Mean ± SEM. ***p < 0.001 versus Veh. MI = 
myocardial infarction; other abbreviations as in Figures 1, 2, and 3. 
We also analyzed the diastolic spontaneous Ca
2+
 release (SCR) such as Ca
2+
 waves or spontaneous 
[Ca
2+
]i transients. Figure 4C illustrates 2 examples of SCR in cardiomyocytes from wt-PMI mice. The 
occurrence of SCR in wt-PMI cardiomyocytes was 4-fold higher than in wt cells (p < 0.001) (Figure 4D). 
However, the occurrence of SCR in Nod1
–/–
-PMI cells was significantly lower than in wt-PMI cells and 
very similar to that obtained in Nod1
–/–
 myocytes (Figure 4D). No changes were found in SCR amplitude 
(measured as F/F0) or Ca
2+
 wave velocity between wt-PMI and Nod1
–/–
-PMI cells (Online Figure 6). 
Supporting these data, blockade of NOD1 with nodinitib-1 in wt-PMI mice prevented the increase of the 
percentage of cells with SCR: 18% in wt-PMI mice treated with nodinitib-1 versus 41% in wt-PMI mice 
treated with vehicle (p < 0.05). 
 
We determined the phosphorylation status of cardiac RyR at Ser
2808
 (primarily protein kinase A 
[PKA] activation site) and at Ser
2814
 (site for calcium/calmodulin-dependent protein kinase II [CaMKII] 
activation). Similar phosphorylation levels of RyR at Ser
2808
 and Ser
2814
 were found in Nod1
–/–
-PMI and 
Nod1
–/–
 cardiac tissue (Figure 4E, Online Figure 7), whereas wt-PMI cardiac tissue had higher levels of 
phosphorylated RyR than wt tissue in both serine residues (Figure 4E, Online Figure 7). Additionally, 
fluorescence resonance energy transfer experiments performed in rabbit cardiomyocytes showed that the 
NOD1 agonist lauroyl γ-D-glutamyl-meso-diaminopimelic acid (iE-DAP) treatment increased cytosolic 
levels of cyclic adenosine monophosphate, a key activator of PKA and a mediator of CaMKII activation 
(Online Figure 8). Furthermore, cardiomyocytes incubated with iE-DAP demonstrated a significant 
increase of SCR that was prevented by a selective PKA inhibitor (KT-5720; Sigma, St. Louis, Missouri) 
or a selective CaMKII inhibitor (KN-93, Sigma) (Figure 4F). Moreover, the treatment of myocytes with 
KT-5720 or KN-93 also prevented the decrease in systolic calcium release and the depressed cell 
contractility induced by the NOD1 agonist, iE-DAP (Online Figure 9). 
 
Next, we found that higher NOD1 protein levels coimmunoprecipitated with RyR in cardiac tissue 
obtained from wt-PMI versus wt, and that increased cardiac NOD1-RyR interaction in the wt-PMI group 
was significantly prevented by nodinitib-1 treatment (Online Figure 10A). We also analyzed whether 
NOD1-RyR association can rapidly regulate Ca
2+
 handling. Compared with vehicle-treated wt 
cardiomyocytes, cells perfused for 3 to 5 min with iE-DAP exhibited a marked decrease in [Ca
2+
]i 
transient amplitude together with a significant decline in cell contraction and SR Ca
2+
 load (Online 
Figures 10B and 10C). Importantly, the inactive iE-DAP analogue, iE-Lys, failed to induce changes in 
Ca
2+
 handling. 
 
In evaluating whether NOD1 modulated the occurrence of ventricular arrhythmias in MI mice after 
isoproterenol treatment, we found that spontaneous ventricular tachycardia (VT) events (Figures 5A and 
5B) and mortality rates (Figure 5C) were significantly higher in wt-PMI mice than in Nod1
–/–
 mice treated 
with isoproterenol. 
  
 
 
 
Figure 5. Antiarrhythmic Effect of NOD1 Deletion 
(A) Representative electrocardiogram obtained in Nod1–/–-PMI mice with 
normal sinus rhythm and in wt-PMI mice with ventricular tachycardia (VT) 
after isoproterenol (Iso) injection. Occurrence of (B) VT and (C) mortality 
induced after Iso treatment of wt-PMI (n = 10) and Nod1–/–-PMI (n = 9) mice. 
(D) Line-scan images from wt cell paced at 2 Hz and perfused with 10-8 mol/l 
Iso (top); abnormal calcium release showing multiple Ca2+ sparks and/or 
spontaneous Ca2+ release during pacing (bottom; arrows = triggered activity; 
red lines = electrical stimuli). The corresponding fluorescence intracellular 
Ca2+ concentration transients profiles appear above in each cell. (E) 
Occurrence of proarrhythmogenic Ca2+ release in myocytes paced at 2 Hz in 
the absence or presence of 10-8 mol/l Iso in wt-PMI (n = 28 cells/4 mice) and 
Nod1–/–-PMI (n = 24 cells/4 mice) cells. Mean ± SEM. (F) Representative 
Western blots of P-RyR at Ser2808/2814 and RyR in wt, wt-PMI, and Nod1–/–-PMI 
hearts from Iso-injected mice. *p < 0.05, ***p < 0.001 versus Wt; #p < 0.05 vs. 
wt-PMI; &p < 0.05 versus Nod1–/–. Abbreviations as in Figures 1, 2, 3, and 4. 
We examined whether VT was associated with Ca
2+
 dynamics impairment at the cellular level. 
Figure 5D shows regular Ca
2+
 release during pacing in a wt myocyte under isoproterenol perfusion (upper 
panel) and a wt-PMI myocyte producing spontaneous [Ca
2+
]i transients and after-contractions under 
electrical stimulation and isoproterenol administration, consistent with triggered activity (lower panel). 
During diastole, wt-PMI cells displayed an increase in SCR that occasionally reached the threshold to 
produce after-contractions and triggered activity. At baseline, the incidence of proarrhythmogenic Ca
2+
 
release in wt-PMI cells was significantly higher than in Nod1
–/–
-PMI cells (Figure 5E). Under 
isoproterenol stimulation, the occurrence of the proarrhythmogenic Ca
2+
 events was significantly 
increased in both groups; however, these events were almost 2-fold-higher in wt-PMI than in Nod1
–/–
-
PMI cardiomyocytes (Figure 5E). 
 
We also examined RyR phosphorylation after isoproterenol administration in wt-PMI and Nod1
–/–
-
PMI hearts. The up-regulation of RyR phosphorylation at Ser
2808/2814
 was significantly reduced in Nod1
–/–
-
PMI versus wt-PMI cardiac tissue (Figure 5F, Online Figure 11). 
  
DISCUSSION 
HF is a complex syndrome associated with low-grade chronic inflammation that leads to deleterious 
cardiac remodeling, but the underlying mechanisms are poorly understood. Here we newly identified 
NOD1 as a factor involved in the failing heart (Central Illustration). Pattern recognition receptor NOD1 
plays a prominent role in the innate immune response to infection. Innate immune receptors can also be 
activated by damage-associated molecular patterns that are present in many cardiovascular disorders, 
including HF (11,12). 
 
 
 
Central Illustration. Involvement of NOD1 in HF 
(A) Heart failure (HF) is associated with hyperphosphorylation of ryanodine receptors 
(RyR) that causes an aberrant increased diastolic Ca2+ release as well as decreased 
sarcoplasmic reticulum Ca2+ load induced by down-regulation of the sarcoplasmic 
reticulum -adenosine triphosphatase (SERCA) and up-regulation of the Na+/Ca2+ 
exchanger (NCX). Decreased sarcoplasmic reticulum Ca2+ load and increased diastolic 
Ca2+ release contribute to reduce systolic Ca2+ release and induce a depressed 
cardiomyocyte contraction. All these changes observed in wild-type post-myocardial 
infarction (wt-PMI) mice were blunted in Nod1–/–-PMI mice, pointing to a relevant role 
of nucleotide-binding oligomerization domain-containing protein 1 (NOD1) in cardiac 
dysfunction associated with HF. (B) Representative 3-dimensional example of 
proarrhythmogenic Ca2+ release obtained in a wt-PMI myocyte during cell pacing (2 
Hz) and a regular Ca2+ release obtained in Nod1–/–-PMI pacing myocyte (2 Hz). P-
RyR = phosphorylation ryanodine receptors. 
NOD1 is ubiquitously expressed in various mammalian organs, including the heart. We showed for 
the first time that human failing myocardium accumulates NOD1, which is associated with increased 
levels of RIP2, its specific adaptor, in cardiomyocytes and increased levels of the proinflammatory factor 
tumor necrosis factor-α. Importantly, NOD1 levels are related to the severity of cardiac dysfunction as 
shown by a negative correlation between NOD1 levels and cardiac output or EF in HF patients. The 
higher NOD1 levels found in failing myocardium does not establish causality, but its continued presence 
in failing hearts suggests a mechanistic role for this protein in the pathogenesis and worsening of HF. 
  
We used an MI-induced HF model to dissect the mechanisms by which NOD1 participates in HF 
progression. Similar to human tissue, the NOD1 pathway was up-regulated in failing hearts of mice and 
deletion of NOD1 ameliorated cardiac dysfunction as determined by echocardiography and CMR. 
Additionally, infarct size was smaller in Nod1
–/–
-PMI mice than in wt-PMI mice and cardiac hypertrophy 
development was significantly reduced. Pharmacological blockade of NOD1 also prevents cardiac 
dysfunction induced after PMI. These data indicated that deletion of NOD1 prevents both functional and 
structural cardiac remodeling in failing hearts, pointing to a role for this pattern recognition receptor in 
HF progression. 
 
Disruptions in EC coupling are well documented in almost all types of HF (9). More common changes 
of EC coupling associated with HF include a reduction in: 1) triggered Ca
2+
 current through L-type 
calcium channel (ICaL); 2) systolic SR Ca
2+
 release through RyR; and 3) reuptake of Ca
2+
 into SR. All of 
these alterations contribute to reduce SR Ca
2+
 load, limiting the amount the SR Ca
2+
 needed to elicit 
regular myocyte contractions. 
 
The possible alteration of ICaL in HF is contentious. Whereas some studies have described a rise in 
ICaL, others have reported no changes or down-regulation of these Ca
2+
 channels (13,14). Nonetheless, the 
majority of studies agreed that failing hearts exhibited depressed intracellular Ca
2+
 cycling and decreased 
SR Ca
2+
 load. Along this line, wt-PMI cells showed decreased systolic Ca
2+
 release and SR Ca
2+
 load, 
underlying the depressed cardiac function of wt failing animals. Importantly, Nod1
–/–
-PMI mice exhibited 
an ameliorated cardiac dysfunction via an intracellular Ca
2+
 handling mechanism (vide infra). In HF, 
deletion of NOD1 or its pharmacological blockade prevents the decline in systolic Ca
2+
 release and in SR 
Ca
2+
 load. The intracellular Ca
2+
 normalization in Nod1
–/–
-PMI mice enables cardiomyocytes to evoke 
regular Ca
2+
 transients and cell contractions, thereby evading, at least in part, the cardiac dysfunction 
found in HF. Importantly, higher NOD1-RyR association in wt-PMI cardiac tissue and the rapid 
regulation of Ca
2+
 handling by a NOD1 agonist support the idea of a functional role for the RyR-NOD1 
association especially during HF, where this interaction increases. 
 
SERCA is a key participant in the control of SR Ca
2+
 load uptake. Decreased SERCA activity was 
documented in human and experimental HF (15), and its reduced activity or expression led to impaired 
SR Ca
2+
 load uptake and diminished SR Ca
2+
 load, compromising systolic SR Ca
2+
 release and impairing 
cardiomyocyte contractility. Compared with wt, wt-PMI cells had a slower time of [Ca
2+
]i transients 
together with a down-regulation of SERCA protein expression. This suggested a decreased SR Ca
2+
 
uptake by the SERCA pump, correlating with the reduced SR Ca
2+
 load in wt failing cells. Conversely, 
NOD1 deletion prevents the impairment of the decay rates of [Ca
2+
]i transients and SERCA down-
regulation. Thus, normalization of SERCA function provoked by the deletion of NOD1 rescues SR Ca
2+
 
content and might contribute to improve cell contractility, ameliorating the cardiac outcome in Nod1
–/–
-
PMI mice. 
 
An additional essential mechanism involved in controlling [Ca
2+
]i content is NCX. HF is associated 
with elevated cytosolic Ca
2+
 levels due to a decrease in Ca
2+
-induced Ca
2+
 release and SERCA activity as 
described earlier, leading to a compensatory rise in NCX. Chronic up-regulation of NCX results in 
maladaptive cardiac remodeling because NCX does not restore SR Ca
2+
 stores, leading to potentially 
proarrhythmogenic events. Our data revealed that failing hearts presented higher expression of NCX 
protein together with a faster rate of decay of caffeine-evoked [Ca
2+
]i transients than sham-operated hearts 
(wt). The constant increase in Ca
2+
 efflux derived from enhanced NCX might contribute to deplete the SR 
Ca
2+
 stores and depress contractility. By contrast, NCX normalization in Nod1
–/–
-PMI cells dampens 
depletion of SR Ca
2+
 stores and prevents triggered activity-derived arrhythmias. 
 
The reduction in the SR Ca
2+
 load can also be related to an increase in the Ca
2+
 leak during diastole. 
Indeed, several studies have reported increased diastolic Ca
2+
 release from the SR in experimental and 
human failing hearts (16,17). This persistent Ca
2+
 diastolic release resulted in reduced SR Ca
2+
 loading, 
compromising the next systolic SR Ca
2+
 release and impairing cell contraction. 
 
We found no changes in the Ca
2+
 spark frequency in wt-PMI cells; this was corroborated by the 
normalization of Ca
2+
 spark frequency by the SR-Ca
2+
 load obtained in each cell and by the calculation of 
the overall spark-mediated Ca
2+
 leak. 
  
Other forms of spontaneous Ca
2+
 diastolic leak (SCR) are implicated in HF, such as Ca
2+
 waves, 
spontaneous Ca
2+
 transients, or image-imperceptible RyR openings. The spontaneous increase in [Ca
2+
]i 
might activate transient inward currents, which are assumed to be arrhythmogenic (18). Moreover, 
increased SCR can lead to delayed after-depolarizations and trigger arrhythmias at least in part through 
NCX activation; this fundamental mechanism of Ca
2+
 homeostasis in cardiomyocytes constitutes a 
potential substrate for certain types of arrhythmias that can be applicable to the myocardium. 
 
Our results demonstrated a major diastolic Ca
2+
 leak in wt-PMI mice manifested as an increased 
occurrence of SCR events. An increase in the levels of RyR phosphorylated at PKA and CaMKII 
activation sites is a potential mechanism for the augmented SCR in wt-PMI mice given that chronic 
phosphorylation of RyR extends the open state of RyR, might promote diastolic SR Ca
2+
 leak that, in turn, 
depletes SR Ca
2+
 stores, and reduces EC coupling. The augmented SCR could be related to a reduction in 
SR Ca
2+
 load and might also promote arrhythmias. By contrast, Nod1
–/–
-PMI myocytes have a low 
incidence of these aberrant events together with a normalization of RyR phosphorylation. Overall, these 
data showed that the prevention of increased SCR during diastole due to normalization of RyR 
phosphorylation in Nod1
–/–
-PMI cells contributes to maintaining the SR Ca
2+
 content, allows regular 
systolic Ca
2+
 release in cardiomyocytes, and prevents triggered arrhythmias. Furthermore, in vitro 
experiments performed in isolated cardiomyocytes demonstrated that the selective inhibition of PKA and 
CaMKII prevents the increase in SCR induced by NOD1 activation, supporting a plausible mechanism by 
which NOD1 regulates the proarrhythmogenic spontaneous Ca
2+
 release in myocytes. Accordingly, the 
regulation of systolic calcium release and cell contractility by the NOD1 agonist through PKA and 
CaMKII, support the idea that both kinases can mediate NOD1 effects in calcium handling in our HF 
mice model. 
 
HF is frequently associated with cardiac arrhythmias, particularly under β-adrenergic stimulation. 
Importantly, 30% to 50% of HF patients die from sudden cardiac death, and most of these deaths are 
linked to ventricular arrhythmias that in many cases are initiated by focal triggered activity involving Ca
2+
 
handling abnormalities. We found that under β-adrenergic stimulation, wt-PMI mice, but not Nod1–/–-PMI 
mice, developed VT resulting from Ca
2+
 handling impairment and had increased rates of sudden death 
presumably due to arrhythmias. These findings suggest that NOD1 deletion protects against VT. We 
propose that the absence of NOD1 prevents VT-derived sudden death by maintaining SR Ca
2+
 content 
and abnormal SR Ca
2+
 release. We corroborated these results at the cellular level, showing that wt-PMI 
cells under β-adrenergic stimulation had increased abnormal Ca2+ release under electrical stimulation that 
was associated with increased phosphorylation of RyR, whereas isoproterenol perfusion of Nod1
–/–
-PMI 
cardiomyocytes had a significantly smaller effect in systolic abnormal Ca
2+
 release. This prevention of 
aberrant Ca
2+
 release in NOD1-deficient cells is associated with a normalization of RyR phosphorylation, 
pointing to a possible mechanism in the prevention of arrhythmias linked to Nod1
–/–
-PMI mice. 
Study limitations 
NOD1 is expressed ubiquitously and although in vitro experiments are an essential tool to understand 
the specific role of NOD1 in the heart, the development of specific in vivo approaches will improve the 
knowledge of the role of this mediator in the cardiac pathophysiology. 
CONCLUSIONS 
Our study demonstrated that NOD1 is involved in HF progression through Ca
2+
 regulation and 
revealed this NLR as a new potential proinflammatory target in the treatment of HF. 
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